Given that TP53 mutations seem to be a key determinant on disease progression for del(11q) CLL cells, we next evaluated drug responses of these isogenic CLL cell lines harboring high‐risk alterations. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.